Yuhan has been granted a patent for pyrrolidine and piperidine compounds that can be used in the treatment and prevention of FAP-mediated diseases. The patent also covers the preparation processes, pharmaceutical compositions, and uses of these compounds. GlobalData’s report on Yuhan gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Yuhan, cancer treatment biomarkers was a key innovation area identified from patents. Yuhan's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11655235B2) discloses a compound of Formula 1, along with its stereoisomers, mixtures of stereoisomers, and pharmaceutically acceptable salts. The compound has various structures, including Formula 1a, 1b, 1c, 1d, and 1e. In Formula 1a, R5 can be either hydrogen or a C1-3alkyl group. The compound can also have R3 groups selected from a group consisting of —NR4R5, —OR4, —C(O)NHR4, —NHC(O)(CH2)mR4, and —NHS(O)2R4, where R4 is a phenyl substituted with 1 to 3 Z groups. The Z groups can be hydroxy, amino, halogen, cyano, nitro, carboxylic acid, C1-5alkyl optionally substituted with 1 to 3 halogens or amino, C2-6alkenyl, C2-6alkynyl, C1-5alkoxy, C1-5alkylthio, mono- or di-C1-5alkylamino, piperazinyl optionally substituted with acetyl, C1-5alkylsulfonylamino, C1-5alkylcarbonylamino, aminosulfonyl, aminocarbonyl, C1-5alkylaminocarbonyl, phenyl, phenoxy, benzyl, benzoyl, phenylaminocarbonyl, pyrazolyl, and benzoxazolyl. Additionally, R4 can be a heterocycle selected from benzo[d][1,3]dioxolyl, dihydrobenzo[1,4]dioxinyl, 2,3-dihydrobenzofuranyl, 2-oxo-1,2-dihydroquinolinyl, and 2-oxo-1,2,3,4-tetrahydroquinolinyl, optionally substituted with 1 to 3 Z groups. Other R4 groups include naphthyl optionally substituted with 1 halogen, and heteroaryl groups such as pyridinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, furanyl, pyrrolyl, thiophenyl, quinolinyl, isoquinolinyl, chromenonyl, quinazolinyl, benzoxazolyl, benzofuranyl, benzothiophenyl, indolyl, indolinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indazolyl, furo[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-c]pyridinyl, isoxazolyl, acridinyl, and naphthyridinyl, optionally substituted with 1 to 3 Z groups. The patent also covers compounds with R3 as a 5- to 12-membered heteroaryl optionally substituted by 1 to 3 Z groups, or as a 3- to 12-membered non-aromatic heterocycle containing nitrogen, optionally substituted by 1 to 3 Z groups. The compound can be used in pharmaceutical compositions with pharmaceutically acceptable excipients. It can also be used to inhibit fibroblast activation protein, treat nonalcoholic hepatosteatosis (NASH), diseases mediated by fibroblast activation protein, cancer, and to inhibit degradation of fibroblast growth factor-21. The diseases mediated by fibroblast activation protein include lipid disorders, diabetes, liver conditions, gastrointestinal conditions, inflammatory disorders, obesity, infections, hyperproliferative disorders, and cardiovascular conditions.
To know more about GlobalData’s detailed insights on Yuhan, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
